ClinicalTrials.gg
CompletedNCT02657889TOPACIOUpdated Dec 1, 2022Results posted

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

A Phase 1/2 interventional study of niraparib and pembrolizumab in Neoplasms, Triple Negative Breast Cancer and Ovarian Cancer, sponsored by Tesaro, Inc.. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
122
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)

02

Conditions studied

  • Neoplasms
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Metastatic Breast Cancer
  • Advanced Breast Cancer
  • Stage IV Breast Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Keywords

  • PARP inhibitor
  • PD-1
  • Niraparib
  • Pembrolizumab
  • Keynote
  • TOPACIO
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 122 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

First submitted before Tesaro, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patient has proven advanced (unresectable) or cancer as outlined below according to study phase and disease type:

    1. Phase 1 patients (breast or ovarian cancer)

      • Patients with advanced or metastatic breast cancer must have disease that is -negative, estrogen receptor-negative, and progesterone receptor-negative (ie, TNBC). Patients with advanced or metastatic disease may have up to 4 lines of cytotoxic therapy. and adjuvant therapies are not counted towards .
      • Patients must have any epithelial (ie, serous, endometroid, mucinous, clear cell) ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator's assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have received up to 5 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy.
    2. Phase 2 patients (breast or ovarian cancer)

      • Patients with advanced or metastatic breast cancer must have TNBC. Patients with advanced or metastatic disease may have received up to 2 lines of cytotoxic therapy. Adjuvant and/or neoadjuvant therapies are not counted in the number of lines of therapy. TNBC patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within 8 weeks from the day of the last platinum administration.
      • Patients must have with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator's assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have had up to 4 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as one line of therapy.
  • available or a fresh biopsy must be obtained prior to study treatment initiation
  • by v1.1
  • (ECOG) 0 or 1
  • Adequate organ function
  • Able to take oral medications
  • Female patient, if of , has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
  • Male patient agrees to use an adequate method of

Main Exclusion Criteria:

  • Patients with primary platinum ovarian cancer (ie, progressive disease on or within 6 months of first-line platinum therapy)
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis Note: Patients previously treated for may be able to participate provided they are stable
  • Patient has a known additional that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer
  • Poor medical risk
  • Condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
  • Pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study
  • Immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment
  • Known history of (HIV) (HIV 1/2 antibodies)
  • Known active or
  • Active disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Prior treatment with an , anti-PD-L1, or anti-PD-L2 agent
  • Prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor
  • Heart-rate interval (QTc) prolongation > 470 msec at screening
  • Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    niraparib plus pembrolizumab

    Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle

    Drug: niraparib · Biological: pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)

    DLTs are defined as: Any treatment-related Grade \>=3 non-hematologic clinical (non-laboratory) adverse event (AE); Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory (lab) abnormality if Medical intervention is required to treat the participant or the abnormality leads to hospitalization or the abnormality persists for \>=7 days; Any treatment-related hematologic toxicity specifically defined as: Thrombocytopenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Neutropenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion; Any treatment-related AE leading to niraparib dose interruption per the following criteria: A dose interruption for a non-DLT lab abnormality lasting \>=14 days, A dose in interruption per dose modification rules for non-hematologic AE leading to \<80 percent (%) of an intended dose being administered.

    Time frame: During Cycle 1, ie, during the first 21 days of treatment

  2. Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

    ORR is defined as the percentage of participants with a confirmed best overall response of Complete Response (CR) or Partial Response (PR), RECIST v1.1 for target lesions as assessed by the Investigator. CR is defined as disappearance of all target lesions, Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.

    Time frame: Up to 40 weeks

Secondary outcomes

  1. Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.

    Time frame: Up to a maximum of 22 months

  2. Phase 2: Number of Participants With TEAEs

    An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.

    Time frame: Up to a maximum of 54 months

  3. Phase 2: Overall Response Rate (ORR) as Measured by Immune-related RECIST (irRECIST)

    ORR by irRECIST is defined as the percentage of participants with a confirmed best overall response of CR or PR using irRECIST. Immune related complete response (irCR) is defined as at least two radiographic determinations of CR, at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of progressive disease \[PD\] at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).

    Time frame: Up to a maximum of 54 months

  4. Phase 2: Duration of Response (DOR) as Measured by RECIST v1.1

    DoR per RECIST v1.1 was defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.

    Time frame: Up to a maximum of 54 months

  5. Phase 2: DOR as Measured by irRECIST

    DOR was defined as the time from the initial response (irCR, irPR or irSD) to progression or death, whichever occurs first. Response was to be assessed using the irRECIST. Immune related complete response (irCR) is at least two radiographic determinations of CR at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of PD at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).

    Time frame: Up to a maximum of 54 months

  6. Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1

    DCR is defined as the percentage of participants who achieved a CR or PR or stable disease (SD) using RECIST (v1.1) as assessed by the investigator.

    Time frame: Up to 40 weeks

  7. Phase 2: DCR as Measured by irRECIST

    DCR is percentage of participants achieving best overall response of confirmed irCR, irPR, or immune-related stable disease (irSD) (lasting at least 5 weeks), according to irRECIST from the first dose date until disease progression/recurrence.

    Time frame: Up to a maximum of 54 months

  8. Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1

    PFS is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Progression is defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.

    Time frame: Up to a maximum of 54 months

  9. Phase 2: PFS as Measured by irRECIST

    Progression free survival is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, or death, whichever comes first. Progression was to be assessed using the Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST). Immune related progressive disease (irPD) is defined as at least two consecutive radiographic determinations of progressive disease (PD - e.g., appearance of one or more new lesions) at least 4 weeks apart).

    Time frame: Up to a maximum of 54 months

  10. Phase 2: Overall Survival (OS)

    OS is defined as the time from date of first dose of study treatment to the date of death by any cause.

    Time frame: Up to a maximum of 54 months

  11. Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib

    Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis of Niraparib was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  12. Phase 1: AUC (0-24) of Major Metabolite of Niraparib (M1)

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  13. Phase 1: Minimum Observed Plasma Concentration (Cmin) and Maximum Observed Plasma Concentration (Cmax) of Niraparib

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  14. Phase 1: Cmin and Cmax of Major Metabolite of Niraparib (M1)

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  15. Phase 1: Apparent Oral Clearance (CL/F) of Niraparib

    Blood samples were planned to be collected for to determine CL/F of Niraparib.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  16. Phase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1)

    Blood samples were planned to be collected for to determine CL/F of major metabolite (M1) of Niraparib.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  17. Phase 1: Volume of Distribution (Vz/F) of Niraparib

    Blood samples were planned to be collected for to determine Vz/F of Niraparib.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  18. Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)

    Blood samples were planned to be collected for to determine Vz/F of major metabolite (M1) of Niraparib.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)

  19. Phase 1: AUC at Steady State (AUC,ss) of Niraparib

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)

  20. Phase 1: AUC,ss of Major Metabolite of Niraparib (M1)

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)

  21. Phase 1: Minimum Observed Plasma Concentration at Steady State (Cmin,ss) and Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Niraparib

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)

  22. Phase 1: Cmin,ss and Cmax,ss of Major Metabolite of Niraparib (M1)

    Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)

  23. Phase 2: Plasma Concentrations of Niraparib

    Blood samples were collected by sparse PK sampling to analyze plasma concentration of Niraparib.

    Time frame: Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)

  24. Phase 2: Plasma Concentrations of Major Metabolite of Niraparib (M1)

    Blood samples were collected by sparse PK sampling to analyze plasma concentration of major metabolite of Niraparib (M1).

    Time frame: Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)

07

Results

Posted Feb 11, 2020

Participant flow

This was a multicenter study conducted in the United States.

Phase 1: (Up to a Maximum of 22 Months)
Participant flow — Phase 1: (Up to a Maximum of 22 Months)
MilestonePhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Started7700
Completed0000
Not completed7700
Withdrew: Death5500
Withdrew: Lost to follow-up2000
Withdrew: Sponsor decision0100
Withdrew: Radiologic disease progression0100
Phase 2: (Up to a Maximum of 54 Months)
Participant flow — Phase 2: (Up to a Maximum of 54 Months)
MilestonePhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Started005355
Completed0000
Not completed005355
Withdrew: Death003042
Withdrew: Lost to follow-up0052
Withdrew: Withdrawal by subject0082
Withdrew: Sponsor decision0022
Withdrew: Radiologic disease progression0061
Withdrew: Physician decision0001
Withdrew: Participant request0021
Withdrew: Participants went on rollover study0004

Outcome measures

PrimaryPhase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)

DLTs are defined as: Any treatment-related Grade \>=3 non-hematologic clinical (non-laboratory) adverse event (AE); Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory (lab) abnormality if Medical intervention is required to treat the participant or the abnormality leads to hospitalization or the abnormality persists for \>=7 days; Any treatment-related hematologic toxicity specifically defined as: Thrombocytopenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Neutropenia Grade 4 for \>=7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion; Any treatment-related AE leading to niraparib dose interruption per the following criteria: A dose interruption for a non-DLT lab abnormality lasting \>=14 days, A dose in interruption per dose modification rules for non-hematologic AE leading to \<80 percent (%) of an intended dose being administered.

Time frame:
During Cycle 1, ie, during the first 21 days of treatment
Reported as:
Count of participants · Participants
Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)
ParticipantsPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)11
PrimaryPhase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

ORR is defined as the percentage of participants with a confirmed best overall response of Complete Response (CR) or Partial Response (PR), RECIST v1.1 for target lesions as assessed by the Investigator. CR is defined as disappearance of all target lesions, Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis; PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.

Time frame:
Up to 40 weeks
Reported as:
Number · Percentage of participants
Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
Percentage of participantsPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.115.1 (7.7 to 25.6)18.2 (10.2 to 28.9)
SecondaryPhase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.

Time frame:
Up to a maximum of 22 months
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)77
SecondaryPhase 2: Number of Participants With TEAEs

An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.

Time frame:
Up to a maximum of 54 months
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With TEAEs
ParticipantsPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200 mg + Pembrolizumab
Phase 2: Number of Participants With TEAEs5354
SecondaryPhase 2: Overall Response Rate (ORR) as Measured by Immune-related RECIST (irRECIST)

ORR by irRECIST is defined as the percentage of participants with a confirmed best overall response of CR or PR using irRECIST. Immune related complete response (irCR) is defined as at least two radiographic determinations of CR, at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of progressive disease \[PD\] at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).

Time frame:
Up to a maximum of 54 months

No measurements were reported for this outcome.

SecondaryPhase 2: Duration of Response (DOR) as Measured by RECIST v1.1

DoR per RECIST v1.1 was defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.

Time frame:
Up to a maximum of 54 months
Reported as:
Median · Months
Phase 2: Duration of Response (DOR) as Measured by RECIST v1.1
MonthsPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200 mg + Pembrolizumab
Phase 2: Duration of Response (DOR) as Measured by RECIST v1.114.4 (8.3 to 18.7)21.5 (8.4 to NA)
SecondaryPhase 2: DOR as Measured by irRECIST

DOR was defined as the time from the initial response (irCR, irPR or irSD) to progression or death, whichever occurs first. Response was to be assessed using the irRECIST. Immune related complete response (irCR) is at least two radiographic determinations of CR at least 4 weeks apart and before Immune related progressive disease (irPD - defined as at least two consecutive radiographic determinations of PD at least 4 weeks apart) at least 4 weeks apart. Immune related partial response (irPR) defined as at least two radiographic determinations of PR or better at least 4 weeks apart and before irPD (and not qualifying for an irCR).

Time frame:
Up to a maximum of 54 months

No measurements were reported for this outcome.

SecondaryPhase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1

DCR is defined as the percentage of participants who achieved a CR or PR or stable disease (SD) using RECIST (v1.1) as assessed by the investigator.

Time frame:
Up to 40 weeks
Reported as:
Number · Percentage of participants
Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.1
Percentage of participantsPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Phase 2: Disease Control Rate (DCR) as Measured by RECIST v1.158.5 (46.3 to 70.0)41.8 (30.5 to 53.8)
SecondaryPhase 2: DCR as Measured by irRECIST

DCR is percentage of participants achieving best overall response of confirmed irCR, irPR, or immune-related stable disease (irSD) (lasting at least 5 weeks), according to irRECIST from the first dose date until disease progression/recurrence.

Time frame:
Up to a maximum of 54 months

No measurements were reported for this outcome.

SecondaryPhase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1

PFS is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Progression is defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.

Time frame:
Up to a maximum of 54 months
Reported as:
Median · Months
Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1
MonthsPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200 mg + Pembrolizumab
Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.13.4 (2.1 to 8.2)2.5 (1.4 to 6.4)
SecondaryPhase 2: PFS as Measured by irRECIST

Progression free survival is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, or death, whichever comes first. Progression was to be assessed using the Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST). Immune related progressive disease (irPD) is defined as at least two consecutive radiographic determinations of progressive disease (PD - e.g., appearance of one or more new lesions) at least 4 weeks apart).

Time frame:
Up to a maximum of 54 months

No measurements were reported for this outcome.

SecondaryPhase 2: Overall Survival (OS)

OS is defined as the time from date of first dose of study treatment to the date of death by any cause.

Time frame:
Up to a maximum of 54 months
Reported as:
Median · Months
Phase 2: Overall Survival (OS)
MonthsPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Phase 2: Overall Survival (OS)17.1 (7.9 to NA)9.4 (3.2 to 22.2)
SecondaryPhase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib

Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis of Niraparib was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Hour*nanogram per milliliter
Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib
Hour*nanogram per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib6524.035 ± 2606.2638855.687 ± 1415.318
SecondaryPhase 1: AUC (0-24) of Major Metabolite of Niraparib (M1)

Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Hour*nanogram per milliliter
Phase 1: AUC (0-24) of Major Metabolite of Niraparib (M1)
Hour*nanogram per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: AUC (0-24) of Major Metabolite of Niraparib (M1)4886.115 ± 975.01111076.538 ± 6691.358
SecondaryPhase 1: Minimum Observed Plasma Concentration (Cmin) and Maximum Observed Plasma Concentration (Cmax) of Niraparib

Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Nanogram per milliliter
Phase 1: Minimum Observed Plasma Concentration (Cmin) and Maximum Observed Plasma Concentration (Cmax) of Niraparib
Nanogram per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Cmin174.00 ± 84.922205.63 ± 196.714
Cmax546.0 ± 195.95711.3 ± 189.98
SecondaryPhase 1: Cmin and Cmax of Major Metabolite of Niraparib (M1)

Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Nanogram per milliliter
Phase 1: Cmin and Cmax of Major Metabolite of Niraparib (M1)
Nanogram per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Cmin42.114 ± 42.76546.677 ± 45.343
Cmax340.14 ± 89.356491.66 ± 226.122
SecondaryPhase 1: Apparent Oral Clearance (CL/F) of Niraparib

Blood samples were planned to be collected for to determine CL/F of Niraparib.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Liters per hour
Phase 1: Apparent Oral Clearance (CL/F) of Niraparib
Liters per hourPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Apparent Oral Clearance (CL/F) of NiraparibNA ± NANA ± NA
SecondaryPhase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1)

Blood samples were planned to be collected for to determine CL/F of major metabolite (M1) of Niraparib.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Liters per hour
Phase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1)
Liters per hourPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Apparent Oral Clearance (CL/F) of Major Metabolite of Niraparib (M1)NA ± NANA ± NA
SecondaryPhase 1: Volume of Distribution (Vz/F) of Niraparib

Blood samples were planned to be collected for to determine Vz/F of Niraparib.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Liters
Phase 1: Volume of Distribution (Vz/F) of Niraparib
LitersPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Volume of Distribution (Vz/F) of NiraparibNA ± NANA ± NA
SecondaryPhase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)

Blood samples were planned to be collected for to determine Vz/F of major metabolite (M1) of Niraparib.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)
Reported as:
Mean · Liters
Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)
LitersPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)NA ± NANA ± NA
SecondaryPhase 1: AUC at Steady State (AUC,ss) of Niraparib

Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Reported as:
Mean · Hour*nanograms per milliliter
Phase 1: AUC at Steady State (AUC,ss) of Niraparib
Hour*nanograms per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: AUC at Steady State (AUC,ss) of Niraparib27396.910 ± 15097.18630799.742 ± 9868.734
SecondaryPhase 1: AUC,ss of Major Metabolite of Niraparib (M1)

Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Reported as:
Mean · Hour*nanograms per milliliter
Phase 1: AUC,ss of Major Metabolite of Niraparib (M1)
Hour*nanograms per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Phase 1: AUC,ss of Major Metabolite of Niraparib (M1)32878.205 ± NA127430.14 ± NA
SecondaryPhase 1: Minimum Observed Plasma Concentration at Steady State (Cmin,ss) and Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Niraparib

Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Reported as:
Mean · Nanograms per milliliter
Phase 1: Minimum Observed Plasma Concentration at Steady State (Cmin,ss) and Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Niraparib
Nanograms per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Cmin,ss878.75 ± 651.122849.00 ± 194.841
Cmax,ss1585.5 ± 812.631606.7 ± 261.02
SecondaryPhase 1: Cmin,ss and Cmax,ss of Major Metabolite of Niraparib (M1)

Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.

Time frame:
Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)
Reported as:
Mean · Nanograms per milliliter
Phase 1: Cmin,ss and Cmax,ss of Major Metabolite of Niraparib (M1)
Nanograms per milliliterPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + Pembrolizumab
Cmin,ss1410.000 ± 207.6863280.000 ± 1460.411
Cmax,ss2177.50 ± 475.0004213.33 ± 1515.333
SecondaryPhase 2: Plasma Concentrations of Niraparib

Blood samples were collected by sparse PK sampling to analyze plasma concentration of Niraparib.

Time frame:
Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)
Reported as:
Median · Nanograms per milliliter
Phase 2: Plasma Concentrations of Niraparib
Nanograms per milliliterPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Cycle 1 Day 1: Predose0.000 ± 0.0000.000 ± 0.000
Cycle 1 Day 1; 2 hours post dose315.979 ± 199.798302.642 ± 267.128
Cycle 2 Day 1; Predose441.978 ± 229.948510.154 ± 263.634
Cycle 2; Day 1; 2 hours post dose764.500 ± 370.140884.185 ± 508.607
SecondaryPhase 2: Plasma Concentrations of Major Metabolite of Niraparib (M1)

Blood samples were collected by sparse PK sampling to analyze plasma concentration of major metabolite of Niraparib (M1).

Time frame:
Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)
Reported as:
Median · Nanograms per milliliter
Phase 2: Plasma Concentrations of Major Metabolite of Niraparib (M1)
Nanograms per milliliterPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + Pembrolizumab
Cycle 1 Day 1; Predose0.000 ± 0.0000.000 ± 0.000
Cycle 1 Day1; 2 hours post dose116.666 ± 89.10884.875 ± 92.206
Cycle 2 Day 1; Predose1278.926 ± 625.9321070.923 ± 648.225
Cycle 2 Day 1; 2 hours post dose1500.143 ± 976.5721205.444 ± 858.698

Adverse events

Collected over All-cause mortality, serious adverse events (SAE) and non-serious adverse events (non-SAEs) were collected up to a maximum of 22 months in Phase 1 and up to a maximum of 54 months in Phase 2 of the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Niraparib 200 mg + Pembrolizumab5/7 (71.4%)6/7 (85.7%)7/7 (100%)
Phase 1: Niraparib 300 mg + Pembrolizumab5/7 (71.4%)4/7 (57.1%)7/7 (100%)
Phase 2 OC: Niraparib 200 mg + Pembrolizumab30/53 (56.6%)22/53 (41.5%)52/53 (98.1%)
Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab42/55 (76.4%)24/55 (43.6%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200 mg + Pembrolizumab
ThrombocytopeniaBlood and lymphatic system disorders1/73/72/534/55
Abdominal painGastrointestinal disorders2/70/71/530/55
NauseaGastrointestinal disorders2/71/72/530/55
AnaemiaBlood and lymphatic system disorders1/70/72/531/55
NeutropeniaBlood and lymphatic system disorders1/70/71/530/55
PancytopeniaBlood and lymphatic system disorders0/71/70/531/55
Abdominal distensionGastrointestinal disorders1/70/70/530/55
AscitesGastrointestinal disorders1/70/70/530/55
ColitisGastrointestinal disorders1/70/70/530/55
Obstruction gastricGastrointestinal disorders1/70/70/530/55
Most frequent other events
Showing 10 of 130
Most frequent other events
EventPhase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200 mg + PembrolizumabPhase 2 TNBC: Niraparib 200 mg + Pembrolizumab
AnaemiaBlood and lymphatic system disorders5/75/719/5324/55
ConstipationGastrointestinal disorders5/72/728/5324/55
NauseaGastrointestinal disorders4/74/732/5334/55
FatigueGeneral disorders4/73/732/5330/55
ThrombocytopeniaBlood and lymphatic system disorders1/74/714/5314/55
VomitingGastrointestinal disorders4/72/721/5313/55
HyponatraemiaMetabolism and nutrition disorders4/73/76/536/55
DyspnoeaRespiratory, thoracic and mediastinal disorders3/74/711/5320/55
Abdominal distensionGastrointestinal disorders3/70/75/533/55
Abdominal painGastrointestinal disorders3/70/713/538/55

Baseline characteristics

The Baseline analysis Population consisted of all participants who received at least one dose of study medication.

Age, Categorical
Age, Categorical(Participants)Phase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + PembrolizumabTotal
<=18 years00000
Between 18 and 65 years44374792
>=65 years3316830
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + PembrolizumabTotal
Female775355122
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + PembrolizumabTotal
Hispanic or Latino10337
Not Hispanic or Latino665051113
Unknown or Not Reported01012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + PembrolizumabTotal
American Indian or Alaska Native00000
Asian00325
Native Hawaiian or Other Pacific Islander00000
Black or African American00189
White774643103
More than one raceNANANANANA
Unknown or Not Reported00325
Region of Enrollment
Region of Enrollment(Participants)Phase 1: Niraparib 200 mg + PembrolizumabPhase 1: Niraparib 300 mg + PembrolizumabPhase 2 OC: Niraparib 200mg + PembrolizumabPhase 2 TNBC: Niraparib 200mg + PembrolizumabTotal
United States775355122
08

Study locations

30 sites
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Phoenix, Arizona 85054, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85258, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Stanford, California 94305, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Deerfield Beach, Florida 33442, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    Boston, Massachusetts 02111, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Morristown, New Jersey 07962, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22903, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Farkkila A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8. Erratum In: Nat Commun. 2020 May 18;11(1):2543. doi: 10.1038/s41467-020-16344-z. PubMed 32193378 ↗
  • Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Farkkila A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. PubMed 31194228 ↗
  • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019 Aug 1;5(8):1132-1140. doi: 10.1001/jamaoncol.2019.1029. PubMed 31194225 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2018, 24 months.

Results were first posted in Feb 2020, 1 year 8 months after primary completion.

Of 194 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 24 months is below that.

Counting every sponsor, half of 296 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 18, 2016
StartActual
Apr 15, 2016
Primary completionActual
May 14, 2018
CompletionActual
Sep 17, 2021
Results first posted
Feb 11, 2020
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02657889
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Jan 18, 2016
Start date
Apr 15, 2016
Primary completion
May 14, 2018
Completion
Sep 17, 2021
Results posted
Feb 11, 2020
Last update
Dec 1, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion